The forthcoming presentations of CF33 at ESMO 2023 in Madrid (20/10/2023) and Vaxinia at SITC 2023 in San Diego (1/11/2023) are eagerly awaited by shareholders.
At the ESMO conference I am expecting to see published results of third party reviewed data of cancer cell biopsies and news headlines along the lines of ... First in human trial of CF33 oncolytic virus confirms that it detects, infects and kills solid tumor cancer cells.
The CHECKvacc Phase 1 Trial in TNBC is in the 4th cohort of a six cohort design with an estimated study completion date of December 1st 2023.
View attachment 5638073As noted previously the published results will not include Cohort 4, however it will update the results of Cohort 3 which were last presented data up to October 2022 at ACCR 2023 in April. Note in an interview discussing the dose escalation to Cohort 3 Leslie quoted this as the potential sweat spot for the study.
While there has been much conjecture that the SITC 2023 conference will provide some indication of data efficacy I note that the presentation is a Trial in Progress Poster which according to ASCO guidelines ...
"trials in progress are ongoing and have not reached pre-specified end points for analysis and as such inclusion of results would be improper and is strictly forbidden"
The Vaxinia MAST trial is a 14 cohort design in both monotherapy and combination with Pembrolizumab administered by intra-tumoral injection and intravenous infusion.
The progress though this trial has been exceptional as we are now in the final two cohorts in monotherapy and with only two cohorts remain in the combination therapy.
View attachment 5638031The majority of cohorts in the MAST study have been dosed at 1x10^7 and there has been no safety concerns to date. This is truly an exceptional outcome.
And while we wait for news of the first patient in on the OnCARlytics OASIS trial I am confident that CF33 will deliver on its promise to obliterate solid tumor cancer cells.
Special thanks to the great team at Imugene under the leadership of LC to progress these trials through the clinic.
GLTAH - Go Team Imugene
(20min delay)